



FOR IMMEDIATE RELEASE

Autolomous and Cellular Origins Expand Platform Integration to Deliver End-to-End Cell Therapy Manufacturing Orchestration

[London and Cambridge 8th July 2026] – Autolomous and Cellular Origins today announce end-to-end integration of their respective platforms, bringing full automation and digitisation to the entire cell therapy manufacturing process. This new scalable approach creates a connected manufacturing environment that gives developers greater standardisation, traceability and control across the entire manufacturing process.

Cellular Origins' Constellation® automated platform enables low-risk cell therapy manufacturing, integrating mobile robotics, existing bioprocessing technologies and sterile fluid transfer into a coordinated operation. Its flexible, modular architecture allows developers and manufacturers to scale manufacturing capacity as demand grows while maintaining standardised processes, avoiding therapy redevelopment and reducing scale-up risk.

Autolomous' digital autoloMATE® platform enables real-time data exchange and integration across existing software and AI systems, as well as devices and robotic platforms across the entire manufacturing process and supply chain, while safeguarding intellectual property. The modular architecture allows each deployment to be configured to customer needs.

The combined solution overcomes fragmentation, limited visibility, and the absence of standardised, interoperable data flows without replacing existing processes, enabling manufacturers to scale to commercially viable levels. First integrations have already been achieved at the Cell and Gene Therapy Catapult Digital and Automation Testbeds, as part of an InnovateUK-funded project.

"Scientific ambition has never been the bottleneck in bringing innovative cell therapy to patients, but the delivery infrastructure has brought many challenges," said Alexander Seyf, CEO of Autolomous. "Together with Cellular Origins, we enable fast and efficient scaling from research through to patient administration, ensuring standardisation, automation and digitisation across the entire process."

Edwin Stone, CEO of Cellular Origins added: "Scaling cell therapy manufacturing is not just a question of employing automation; it requires a manufacturing system that can evolve with demand. Our collaboration with Autolomous – and joint work with the Cell and Gene Therapy Catapult – clearly demonstrates how robotic platforms and digital infrastructure can operate as one."

About Autolomous

Autolomous helps life sciences customers worldwide achieve significant cost and time savings and build resilient manufacturing and supply chains through end-to-end digitisation. Powered by

Cellular Origins Ltd

TTP Campus, Cambridge Road, Melbourn, SG8 6HQ

+44 1763 262626 | www.cellularorigins.com

Registered number: 13910732



advanced technology and artificial intelligence, autoloMATE is a cloud-native, modular platform that integrates seamlessly with existing systems. By creating a digital backbone across manufacturing and supply chain operations – from planning through release – autoloMATE delivers measurable gains in productivity, scalability, and cost-effectiveness. Its modular architecture allows each deployment to be configured precisely to customer needs, while the intuitive design ensures ease of use across the organisation. Explore more at www.autolomous.com.

About Cellular Origins www.cellularorigins.com

Cellular Origins is enabling the manufacture of cell therapies at scale through a flexible, factory-led automation platform that adapts to existing processes and facilities. Its Constellation ecosystem unites mobile robotics, and automated sterile welding with proven bioprocess instruments, eliminating the need for therapy redevelopment and providing a dependable route from clinical to commercial manufacture. Designed to flex around any facility and to evolve with advancing therapies, the Constellation platform provides a flexible, future-proof foundation for large scale production and wider ATMP growth. Trusted by market leaders including Cytiva, Fresenius Kabi, Thermo Fisher Scientific and Wilson Wolf, Cellular Origins is building the automation infrastructure required to scale manufacture of 100,000s of doses of transformative therapies reliably and efficiently.

Cellular Origin media contact:

kdm communications

Lauren Owen

Lauren@kdm-communications.com

Autolomous media contact:

Neil Hunter

Hunter PR

neil@hunterpr.biz

+44 7821 255568